Validation of original and alternative fistula risk scores in postoperative pancreatic fistula

Youngju Ryu · Sang Hyun Shin · Dae Joon Park · Naru Kim · Jin Seok Heo · Dong Wook Choi · In Woong Han

Published online: 1 July 2019
© 2019 The Authors. Journal of Hepato-Biliary-Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Abstract

Background In 2013, the fistula risk score (FRS) was developed to assess the risk of clinically relevant postoperative pancreatic fistula (CR-POPF). In 2017, the alternative FRS (a-FRS) was proposed. The purpose of this study was to validate the original FRS (o-FRS) and a-FRS for CR-POPF in pancreaticoduodenectomy (PD).

Methods From January 2007 to December 2016, 1,771 patients underwent PD for periampullary cancers. POPF was defined and classified according to the 2016 International Study Group for Pancreatic Fistula. All data were reviewed retrospectively.

Results Pathologic diagnosis other than ductal adenocarcinoma (P < 0.001), pancreas duct diameter (P < 0.001), and body mass index (P < 0.001) were independent risk factors for CR-POPF. Pancreatic texture (P = 0.534) and estimated blood loss (P = 0.827) were not associated with CR-POPF. The CR-POPF incidence increased with increasing o-FRS score (P < 0.001), and also increased statistically significantly with increasing a-FRS in the higher risk group (P < 0.001). However, the correlations differed. The area under the curve was 0.629 for o-FRS and 0.622 for a-FRS.

Conclusions Both o-FRS and a-FRS might reflect CR-POPF incidence, but some risk factors had no or low statistical significance. Further research is needed to revise the FRS.

Keywords Fistula risk score · Pancreaticoduodenectomy · Postoperative pancreatic fistula · Risk factor · Validation

Introduction

Postoperative pancreatic fistula (POPF) is the most critical complication after pancreaticoduodenectomy (PD), a procedure that has been used worldwide for many years. As surgeons have accrued experience with PD and improved their surgical skills, the associated risks have decreased, postoperative management has been systematized, and patient burden has decreased [1, 2]. Nevertheless, POPF remains a problem for hepatopancreato-biliary surgeons because it causes major complications after PD, increases hospital stay, significantly affects morbidity and mortality, and is a major contributor to medical care costs [3, 4].

Many studies have focused on predicting and preventing clinically relevant POPF (CR-POPF), including several analyses that have proposed various CR-POPF risk factors. However, the ability to accurately predict CR-POPF remains controversial (and potentially impossible) because many studies lack statistical validity due to small sample sizes or other design issues [5–7]. A fistula risk score (FRS) was first proposed by Callery et al. in 2013 [8]. Since the original FRS (o-FRS) was presented, many validation studies and studies seeking a new POPF prediction model have been conducted [9–12]. Studies have shown that not all FRS factors are statistically significant, especially volume of intraoperative blood loss (EBL), suggesting that FRS models should be modified [12, 13]. In
2017, a more reliable FRS was proposed. This alternative FRS (a-FRS) comprises three factors: pancreatic texture, pancreatic duct diameter, and body mass index (BMI) [14]. This study examined the statistical significance of each factor in the o-FRS and a-FRS. Neither the o-FRS nor a-FRS has been validated in a large number of Korean patients. We aimed to validate both FRS methods and determine if the models are useful for Korean patients.

Methods

Patients and surgical methods

Data were reviewed retrospectively from January 2007 to December 2016. This work was approved by our Institutional Review Board (approval number: 2017-07-015-002). Analyses included patients who underwent PD (comprising Whipple’s operation, pylorus-preserving PD, and pylorus-resecting PD) by four experienced, skilled surgeons at a single, high-volume center. The study only included patients diagnosed with periampullary cancer (including ampulla of vater cancer, common bile duct cancer, duodenal cancer, and pancreas cancer) by postoperative pathologic diagnosis. Patients who underwent surgery for metastatic cancer or double primary cancer were excluded. Most patients underwent pancreaticojejunostomy (PJ) with the duct-to-mucosa method for pancreatic-intestinal anastomosis.

Risk factor analysis for pancreatic fistula

To study o-FRS and a-FRS, data were collected and analyzed for five factors: pancreatic gland texture, pancreatic duct size, pathological diagnosis, EBL, and BMI. For both o-FRS and a-FRS, pancreatic gland texture was classified as soft or not soft [8, 14] based on operation records. Pancreatic duct size data was also determined from operation records. Pancreatic duct diameter not recorded in the operation record was treated as a missing value. CR-POPF was classified according to the updated International Study Group of Pancreatic Fistula definition published in 2016 [15].

Overall baseline characteristics are represented with descriptive statistics. Linear-by-linear association was used to assess the relationships between o-FRS score and CR-POPF occurrence and between o-FRS and a-FRS groups and CR-POPF occurrence. Fisher’s exact and Mann–Whitney tests were used to analyze correlations among the five baseline characteristics and CR-POPF occurrence. Logistic regression was calculated with a multivariate analysis of factors and CR-POPF occurrence. Area under the receiver operating curves (AUCs) was calculated to evaluate the efficiency of each FRS model for predicting CR-POPF. IBM SPSS version 23.0 (IBM, Armonk, NY, USA) was used for all statistical analyses.

Results

From January 2007 to December 2016, a total of 1,847 patients underwent PD for various periampullary diseases at Samsung Medical Center. The patients were excluded if they lacked a POPF record (n = 5) or if they had a hepato-pancreatoduodenectomy (n = 21), iatrogenic injury to the pancreas during surgery (n = 1), direct invasion of another organ (n = 14), metastasis from another organ (n = 16), double primary cancer (n = 12), or cancer recurrence (n = 7). A total of 1,771 patients were included in this study. Patient clinical characteristics are described in Table 1. There were included data on 222 CR-POPF patients (12.5%). For pancreatic anastomosis, 10 cases involved pancreaticogastrostomy and other methods, while 1,761 cases (99.5%) used pancreaticojejunostomy. For patients who had the pancreatic anastomosis method recorded, only 12 (0.7%) were performed with an invagination method while 1,731 (99.3%) were performed with a duct-to-mucosa anastomosis. Baseline FRS factors are summarized in Table 2.

The risk factor analysis showed a correlation between FRS factors and the development of CR-POPF in univariate and multivariate analyses (Table 3). Univariate analysis revealed that soft pancreatic texture (P = 0.004),

Table 1 Clinical characteristics of patients included in this study

| Variable                      | N (total n = 1,771) (%) |
|-------------------------------|-------------------------|
| Age                           | 62.35 (18-92)           |
| Sex                           |                         |
| Male                          | 1,080 (61.0)            |
| Female                        | 691 (39.0)              |
| BMI (kg/m²)                   | 23.16 (14.4–39.7)       |
| Pancreatic fistula            |                         |
| No fistula                    | 882 (49.8)              |
| Biochemical leak              | 667 (37.7)              |
| ISGPF grade B                 | 210 (11.9)              |
| ISGPF grade C                 | 12 (0.7)                |
| Specific treatment            |                         |
| Use antibiotics               | 202 (11.4)              |
| Total parenteral nutrition    | 57 (3.2)                |
| Percutaneous drainage         | 99 (5.6)                |

BMI body mass index, ISGPF International Study Group of Pancreatic Fistula
Table 2 Baseline characteristics of fistula risk score factors

| Variable                                | N (total n = 1,771) (%) |
|-----------------------------------------|-------------------------|
| Gland texture                           |                         |
| Firm                                    | 1,021 (57.7)            |
| Soft                                    | 750 (42.4)              |
| Pathology                               |                         |
| PDAC                                    | 568 (32.1)              |
| Other*                                  | 1,203 (67.9)            |
| Pancreatic duct size (median, mm)       | 3.00 (0.2–35)           |
| FRS diameter distribution               |                         |
| ≥5                                      | 456 (25.8)              |
| 4                                       | 210 (11.9)              |
| 3                                       | 439 (24.8)              |
| 2                                       | 445 (25.1)              |
| ≤1                                      | 175 (9.9)               |
| EBL (median, ml)                         | 400 (25–6,000)          |

FRS, fistula risk score; PDAC, pancreatic ductal adenocarcinoma; EBL, estimated blood loss.

Table 3 Univariate and multivariate analysis of FRS factor and CR-POPF

| Risk factor                                | Univariate          | Multivariate        |
|--------------------------------------------|---------------------|---------------------|
|                                            | OR 95% CI P         | OR 95% CI P         |
| Gland texture (soft)                       | 1.52 1.14–2.01 0.004| 1.10 0.82–1.48 0.534|
| Pathology (not PDAC)                       | 3.14 2.13–4.64 <0.001| 2.72 1.83–4.03 <0.001|
| Pancreatic duct size, per mm increase      | 0.83 0.76–0.91 <0.001| 0.87 0.80–0.94 0.001|
| Estimated volume loss                      | 1.00 1.00–1.00 0.827|                     |
| BMI                                        | 1.11 1.07–1.16 <0.001| 1.09 1.05–1.14 <0.001|

BMI, body mass index; CI, confidence interval; OR, odds ratio; PDAC, pancreatic ductal adenocarcinoma.

pathologic diagnosis other than pancreatic ductal adenocarcinoma (PDAC) (P < 0.001), pancreatic duct diameter (P < 0.001), and BMI (P < 0.001) were statistically significant risk factors associated with CR-POPF. Multivariate analysis revealed that a pathologic diagnosis other than PDAC (odds ratio [OR] 2.72, 95% confidence interval [CI] 1.83–4.03, P < 0.001), pancreatic duct diameter per millimeter increase (OR 0.87, 95% CI 0.80–0.94, P = 0.001), and BMI (OR 1.09, 95% CI 1.05–1.14, P < 0.001) were independent risk factors of CR-POPF. Soft pancreatic texture was not significant in the multivariate analysis. Volume of intraoperative blood loss was not associated with CR-POPF.

Figure 1 shows the distribution of o-FRS scores, o-FRS groups, and a-FRS groups. As o-FRS score increased, CR-POPF incidence increased significantly (P < 0.001) (Fig. 1a). According to o-FRS group classification, 1,311 patients (74.0%) had moderate or high risk (Fig. 1b). CR-POPF incidence was 14.6% in the moderate-risk group and 17% in the high-risk group. CR-POPF incidence increased significantly with increasing o-FRS group (P < 0.001) (Fig. 1b, o-FRS group). The a-FRS score is the probability of CR-POPF divided by the group score to show the CR-POPF occurrence rate. A similar number of individuals (1,252 patients, or 70.7%) were in the a-FRS intermediate- and high-risk groups as were in the corresponding o-FRS groups. CR-POPF occurred in 6.7% of patients in the low-risk group, 13.4% in the intermediate-risk group, and 21.6% in the high-risk group. The a-FRS group was significantly associated with CR-POPF (P < 0.001).

A receiver operating curve was used to assess the diagnostic value of o-FRS and a-FRS (Fig. 2). The area under the curve (AUC) was similar for the two FRS models. For o-FRS, the AUC was 0.629 (95% CI 0.59–0.67) (Fig. 2a); for a-FRS, the AUC was 0.622 (95% CI 0.59–0.66) (Fig. 2b).

Discussion

Since o-FRS was introduced, several validation studies and modified predictive models have been published [9–12]. Studies focused on o-FRS have been limited by an inability to show statistical significance due to small sample size, inclusion of data from only one institution, and a lack of external validation [16–18]. In contrast, a study of a-FRS included a large number of patients, collected data from 18 centers, and extended external validation internationally [14]. Thus, we chose these two models for validation. In addition, both models were designed for non-Asian patients, leaving their applicability to a Korea sample open to investigation. Many studies and risk factor analyses have been performed for POPF in Korea, but no study has validated FRS in a large number of Korean patients [19, 20]. Therefore, this study is clinically significant for validation both of o-FRS, which is most widely used for predicting POPF, and a-FRS, which is considered the most reliable validation model.
While accurately measuring EBL and ensuring objectivity are difficult, we showed that EBL, which is a factor in o-FRS but not a-FRS, was not a risk factor for CR-POPF. Other studies have also shown that EBL is not a prognostic factor of POPF [12, 13]. For example, a recent multicenter study in Korea showed that EBL was not a risk factor for POPF but was related to intraoperative fluid volume. Excess fluid can induce edema of the jejunum, causing anastomosis tension of pancreaticojejunostomy and POPF [21]. These findings suggest that EBL itself is not a POPF risk factor, and further studies should be conducted to assess intraoperative fluid volume.

In previous studies, soft pancreatic texture was a risk factor of CR-POPF. Some models include soft pancreatic texture in predicting CR-POPF [18, 22]. This study demonstrated an association between soft pancreatic texture and CR-POPF. In univariate analysis, soft pancreatic texture was a risk factor of CR-POPF. However, in the multivariate analysis, soft pancreatic texture was not an independent prognostic factor of CR-POPF. This difference between the univariate and multivariate analyses can be explained several ways. Our study was retrospective, so the assessments are subjective because surgeons had different criteria for judging pancreatic texture. A meta-analysis showed that soft pancreatic texture is not a risk factor of CR-POPF [16]. Patients with pancreas head cancer are susceptible to obstructive pancreatitis, which can cause pancreatic fibrosis [23]. Thus, pancreas pathology and pancreatic texture are related through inflammation. Finally, this center performs an extremely high number of PDs, averaging 200 or more per year. High-volume centers have standardized procedures, a number of experienced surgeons, and relatively low complication rates [24].

This study indicates that, for a-FRS, BMI is an independent risk factor for CR-POPF. Previous studies have also shown that BMI is a risk factor for CR-POPF [25, 26]. Studies show that visceral fat distribution is important for CR-POPF development. Many studies have reported the effects of sarcopenia or sarcopenic obesity on PD [27–29]. BMI, sarcopenia, and sarcopenic obesity are considered to be related factors. Therefore, to better understand the correlation of these factors, a risk factor analysis should be performed with BMI and sarcopenia or sarcopenic obesity.
The pancreatic duct diameter is a well-known factor for CR-POPF development. This finding has been demonstrated not only in o-FRS and a-FRS, but in many other validation studies [9, 10, 12, 13, 22]. In this study, pancreatic duct diameter was an independent prognostic factor for CR-POPF incidence in univariate and multivariate analyses. Our results agree with several previous studies, and they have a larger sample size. Therefore, pancreatic duct diameter remains an important risk factor for CR-POPF.

In this validation, the AUC was 0.629 for o-FRS and 0.622 for a-FRS (Fig. 2). This result indicates that, although the factors in both FRS models were significant risk factors, both models have questionable predictive value for CR-POPF [30]. Considering the results of previous studies [5–7, 9–12], the similarity of the two model AUC values in this study, despite the different correlation of each risk factor with occurrence of POPF, suggests that additional factors affecting the occurrence of POPF should be considered. This study confirmed that o-FRS and a-FRS require a supplementary factor, and a nomogram was created to predict POPF.

This research has several limitations. We used retrospective data, which could have led to selection bias. This study only included data from a single center, which decreases the strength of statistical analyses. A disadvantage of single-center studies is that the sample does not represent the entire patient population. These results, therefore, may not reflect nationwide data. However, by using data from one center, the surgical technique was consistent for all patients. Despite the limitations listed here, we included a large number of patients.

Conclusion

Both o-FRS and a-FRS significantly predicted POPF. However, neither EBL nor soft pancreatic texture, which are included in both FRS models, were significant in our analyses. Neither model had sufficient diagnostic value. Therefore, to more accurately predict CR-POPF, further research is needed to revise these models.

Acknowledgments This study was supported by Samsung Medical Center grant (grant number: SMX1180101). The authors would like to thank Hyemin Kim (data manager, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) for help with data collection.

Conflict of interest None declared.

References

1. van Berge Henegouwen MI, De Wit LT, Van Gulik TM, Oertop H, Gouma DJ. Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant. J Am Coll Surg. 1997;185:18–24.
2. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786–95.
3. Pratt WB, Maithel SK, Vanounou T, Huang ZS, Callery MP, Vollmer CM Jr. Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPS) classification scheme. Ann Surg. 2007;245:443–51.
4. Ahmad SA, Edwards MJ, Sutton JM, Grewal SS, Hanseman DJ, Maithel SK, et al. Factors influencing readmission after pancreaticoduodenectomy: a multi-institutional study of 1302 patients. Ann Surg. 2012;256:529–37.
5. Wellner UF, Kayser G, Lapshyn H, Sick O, Makowiec F, Hopffer J, et al. A simple scoring system based on clinical factors related to pancreatic texture predicts postoperative pancreatic fistula preoperatively. HPB (Oxford). 2010;12:696–702.
6. Pratt WB, Callery MP, Vollmer CM Jr. Risk prediction for development of pancreatic fistula using the ISGPS classification scheme. World J Surg. 2008;32:419–28.
7. Ansorge C, Strother L, Andren-Sandberg A, Lundell L, Her- rington MK, Segersvard R. Structured intraoperative assessment of pancreatic gland characteristics in predicting complications after pancreaticoduodenectomy. Br J Surg. 2012;99:1076–82.
8. Callery MP, Pratt WB, Kent TS, Chaihof EL, Vollmer CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreaticoduodenectomy. J Am Coll Surg. 2013;216:1–14.
9. Miller BC, Christein JD, Behrman SW, Dredin JA, Pratt WB, Callery MP, et al. A multi-institutional external validation of the fistula risk score for pancreaticoduodenectomy. J Gastrointest Surg. 2014;18:172–9.
10. Roberts KJ, Sutcliffe RP, Manudanayagam R, Hodson J, Isaac J, Mutisian P, et al. Scoring system to predict pancreatic fistula after pancreaticoduodenectomy: a UK multicenter study. Ann Surg. 2015;261:1191–7.
11. McMillan MT, Soi S, Ashun HJ, Ball CG, Bassi C, Beane JD, et al. Risk-adjusted outcomes of clinically relevant pancreatic fistula following pancreaticoduodenectomy: a model for performance evaluation. Ann Surg. 2016;264:344–52.
12. Grendar J, Jutric Z, Leal JN, Ball CG, Bertens K, Dixon E, et al. Validation of fistula risk score calculator in diverse North American HPB practices. HPB (Oxford). 2017;19:508–14.
13. Shubert CR, Wagie AE, Farnell MB, Nagorney DM, Que FG, Reid Lombardo KM, et al. Clinical risk score to predict pancreatic fistula after pancreaticoduodenectomy: independent external validation for open and laparoscopic approaches. J Am Coll Surg. 2015;221:689–98.
14. Munroop TH, van Rijsen LB, van Klaveren D, Smits FJ, van Woerden V, Linnemann RJ, et al. Alternative fistula risk score for pancreaticoduodenectomy (a-FRS)? HPB (Oxford). 2017;19:689–98.
15. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.
16. Vallance AE, Young AL, Macutkiewicz C, Roberts KJ, Smith AM. Calculating the risk of a pancreatic fistula after a pancreaticoduodenectomy: a systematic review. HPB (Oxford). 2015;17:1040–8.
17. Bertens KA, Crown A, Clanton J, Alemi F, Alseidi AA, Biehl T, et al. What is a better predictor of clinically relevant postoperative pancreatic fistula (CR-POPF) following pancreaticoduodenectomy (PD): postoperative day one drain amylase (POD1DA) or the fistula risk score (FRS)? HPB (Oxford). 2017;19:75–81.
18. Casadei R, Ricci C, Taffurelli G, Pacilio CA, Di Marco M, Pagano N, et al. Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy. Int J Surg. 2017;48:189–94.

19. Shin HW, Kim JK, Park JS, Yoon DS. Can we predict postoperative pancreatic leakage after pancreaticoduodenectomy using preoperative fecal elastase-1 level? J Clin Lab Anal. 2013;27:379–83.

20. Lee TK, Kang CM, Park MS, Choi SH, Chung YE, Choi JY, et al. Prediction of postoperative pancreatic fistulas after pancreatectomy: assessment with acoustic radiation force impulse elastography. J Ultrasound Med. 2014;33:781–6.

21. Han IW, Kim H, Heo J, Oh MG, Choi YS, Lee SE, et al. Excess intraoperative fluid volume administration is associated with pancreatic fistula after pancreaticoduodenectomy: a retrospective multicenter study. Medicine (Baltimore). 2017;96:e6893.

22. Casadei R, Ricci C, Taffurelli G, D’Ambra M, Pacilio CA, Ingaldi C, et al. Are there preoperative factors related to a “soft pancreas” and are they predictive of pancreatic fistulas after pancreatic resection? Surg Today. 2015;45:708–14.

23. Minato Y, Kamisawa T, Tabata T, Hara S, Kuruma S, Chiba K, et al. Pancreatic cancer causing acute pancreatitis: a comparative study with cancer patients without pancreatitis and pancreatitis patients without cancer. J Hepatobiliary Pancreat Sci. 2013;20:628–33.

24. Mehta HB, Parmar AD, Adhikari D, Tamirisa NP, Dimou F, Jupiter D, et al. Relative impact of surgeon and hospital volume on operative mortality and complications following pancreatic resection in Medicare patients. J Surg Res. 2016;204:326–34.

25. House MG, Fong Y, Arnaoutakis DJ, Sharma R, Winston CB, Proctor M, et al. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg. 2008;12:270–8.

26. Shimoda M, Katoh M, Yukihiro I, Kita J, Sawada T, Kubota K. Body mass index is a risk factor of pancreatic fistula after pancreaticoduodenectomy. Am Surg. 2012;78:190–4.

27. Sandini M, Bernasconi DP, Ippolito D, Nespoli L, Baini M, Barbaro S, et al. Preoperative computed tomography to predict and stratify the risk of severe pancreatic fistula after pancreateoduodenectomy. Medicine (Baltimore). 2015;94:e1152.

28. Pecorelli N, Carrara G, De Cobelli F, Cristel G, Damascelli A, Balzano G, et al. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg. 2016;103:434–42.

29. Pecorelli N, Capretti G, Sandini M, Damascelli A, Cristel G, De Cobelli F, et al. Impact of sarcopenic obesity on failure to rescue from major complications following pancreaticoduodenectomy for cancer: results from a multicenter study. Ann Surg Oncol. 2018;25:308–17.

30. Carter JV, Pan J, Ral SN, Galandiuk S. ROC-ing along: evaluation and interpretation of receiver operating characteristic curves. Surgery. 2016;159:1638–45.